Rare, serious alemtuzumab adverse events emerge

Despite these good outcomes, the authors of the report note that longer-term outcomes in this AAC population are not yet understood.

The findings led to the addition of AAC to the Warnings and Precautions section of the alemtuzumab label in October 2017.

None of the reports received funding. Some of the authors had financial ties to the pharmaceutical industry.

SOURCES: Croteau D et al. Neurology. 2018 Mar 30. doi: 10.1212/WNL.0000000000005422. Saarela M et al. Neurology. 2018 Mar 30. doi: 10.1212/WNL.0000000000005420. Ferraro D et al. Neurology. 2018 Mar 30. doi: 10.1212/WNL.0000000000005417.